Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 27, 2025Journal of Clinical ApheresisOpen Access

A Descriptive 5‐Year Analysis of the Demographics and Therapies for Patients With Immune Thrombotic Thrombocytopenic Purpura in the USA : A Multicenter Study of 390 Disease Episodes From 2017 to 2021

View Full Paper
Ask AI
Bookmark
Share

Authors

JJJeremy W. JacobsVanderbilt UniversityGBGarrett S. BoothVanderbilt UniversityCSC StanekNatural History Museum Vienna

Discussion

Loading...

Member takes

Overview

Multicenter retrospective study reveals varied therapies and low caplacizumab adoption in immune thrombotic thrombocytopenic purpura episodes, suggesting a need for standardized treatment regimens.

Key Points

  • To characterize patient demographics, apheresis practices, and pharmacological treatments across clinical episodes of immune thrombotic thrombocytopenic purpura in the United States.
  • Retrospective multicenter registry study conducted across 15 comprehensive care sites in the United States between January 1, 2017, and December 31, 2021.
  • Analyzed 390 disease episodes (including initial presentations and relapses) among 280 unique individuals (187 females, 93 males) evaluated for treatment modalities, therapeutic plasma exchange regimens, and survival outcomes.
  • Thirty-day mortality was 3.7% (14/374) and 6-month mortality reached 7.4% (27/367) across evaluated episodes.
  • Therapeutic plasma exchange was performed in 261 episodes with a median of 6 procedures (IQR 3–11), and 82.0% (214/261) of these procedures exclusively utilized plasma replacement fluids.
  • Caplacizumab was administered either as monotherapy or in combination regimens in 11.0% (43/390) of documented episodes.

Cite This Study

Jacobs et al. (2025) studied this question.

synapsesocial.com/papers/6aab67412808766ffbf9926dhttps://doi.org/10.1002/jca.70017
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1IMMUNE THROMBOTIC THROMBOCYTOPENIC PURPURA: PATHOPHYSIOLOGY, DIAGNOSIS AND OPEN ISSUES.2024 · 5 citations
  2. 2Personalised treatment of patients with immune thrombotic thrombocytopenic purpura2025
  3. 3Real-World Data Analysis of Patients Affected by Immune-Mediated Thrombotic Thrombocytopenic Purpura in Italy2024 · 2 citations
  4. 4#1491 Management of immune thrombotic thrombocytopenic purpura without therapeutic plasma exchange2024 · 1 citations
  5. 5Prognostic Relevance of Early Clinical and Laboratory Findings in Immune-Mediated Thrombotic Thrombocytopenic purpura2025